Total Funding
6
52
Total FundingPre-Seed raised
Growth Score
2 pts
Heat Score
-15 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
151712
We use patented CRISPR technology to produce non-addictive opiates for pain management in collaboration with Merck Pharmaceuticals Germany
About the Company
Emerzene is a gene editing company that is changing the way CRISPR is used in plants to create non-addictive opiates for pain relief and cancer research. It aims to develop a line of plant-based morphine-free medicines that are affordable and can help to reduce drug abuse and addiction.
